Pregnancy
There are no clinical data from the use of Benzydamine Mouthwash during pregnancy.
During the third trimester of pregnancy, systemic use of prostaglandin synthetase inhibitors may induce cardiopulmonary and renal toxicity in the fetus. At the end of the pregnancy prolonged bleeding time in both mother and child may occur, and labour can be delayed.
It is not known if the systemic Benzydamine Mouthwash exposure reached after topical administration can be harmful to an embryo/fetus.
Therefore, Benzydamine Mouthwash should not be used during pregnancy unless clearly necessary. If used, the dose should be kept as low and duration of treatment as short as possible.
There is no evidence of a teratogenic effect in animal studies (see section 5.3).
From the 20th week of pregnancy onward, Benzydamine Mouthwash use may cause oligohydramnios resulting from foetal renal dysfunction. This may occur shortly after treatment initiation and is usually reversible upon discontinuation. In addition, there have been reports of ductus arteriosus constriction following treatment in the second trimester, most of which resolved after treatment cessation. Therefore, during the first and second trimester of pregnancy, Benzydamine Mouthwash should not be given unless clearly necessary. If Benzydamine Mouthwash is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible. Antenatal monitoring for oligohydramnios and ductus arteriosus constriction should be considered after exposure to Benzydamine Mouthwash for several days from gestational week 20 onward. Benzydamine Mouthwash should be discontinued if oligohydramnios or ductus arteriosus constriction are found. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to:
- cardiopulmonary toxicity (premature constriction/closure of the ductus arteriosus and pulmonary hypertension);
- renal dysfunction (see above);
the mother and the neonate, at the end of pregnancy, to:
- possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses;
- inhibition of uterine contractions resulting in delayed or prolonged labour.
Consequently, Benzydamine Mouthwash is contraindicated during the third trimester of pregnancy (see sections 4.3).
Breast-feeding
It is not known whether benzydamine hydrochloride / metabolites are excreted in human milk. Benzydamine Mouthwash should not be used during breastfeeding unless considered essential by the physician.
Fertility
There is no evidence of a teratogenic effects in studies (see section 5.3). It is not known whether treatment with Benzydamine Mouthwash affected fertility in humans.